A new study sponsored by Mirvie, which is the first to evaluate U.S. Preventive Services Task Force (USPSTF) guidelines for preeclampsia risk and aspirin prescription in a single, nationally representative, prospective population, found while high-risk factors had sufficient value in estimating risk, there’s limited value for the moderate risk category – leading to nonspecific recommendations for aspirin use, a recognized prevention tool.